natgillin/translations-raw huggingface dataset:
Care should be taken to ensure that the content of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Poskrbite, da vsebina pipete ali nanešen odmerek ne pride v stik z očmi ali usti zdravljene živali in/ ali drugih živali.
It is therefore recommended to treat the animals during the evening and that recently treated animals are not allowed to sleep with owners, especially children.
Pravkar zdravljene živali ne smejo spati z lastniki, še posebej ne z otroci.
A dry residue may also be observed.
Nanos zdravila lahko lokalno povzroči začasen masten izgled, vozlanje in zlepljanje dlake na mestu nanosa.
This is normal and will generally resolve within 1 – 4 days after administration.
Opazen je lahko tudi suh ostanek, ki se razgradi v 1 – 4 dneh po dajanju.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation in queens.
Varnost zdravila ni bila raziskana pri brejih in doječih mačkah.
Laboratory studies with metaflumizone in rats and/ or rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
Z laboratorijskimi študijami na podganah in/ ali zajcih niso bili dokazani teratogeni in fetotoksični učinki ter toksični učinki na mater.
Use only according to the benefit/ risk assessment by the responsible veterinarian.
Uporabite le v skladu z oceno razmerja koristi/ tveganja odgovornega veterinarja
The recommended minimum dose is 40 mg metaflumizone/ kg bodyweight, equivalent to 0.20ml/ kg bodyweight.
Priporočen minimalen odmerek je 40 mg metaflumizona/ kg telesne mase, kar ustreza 0, 20 ml/ kg telesne mase.
3
3 Telesna masa mačke
ProMeris for Small Cats ProMeris for Large Cats
ProMeris za velike mačke
Apply the content of the pipette to a single spot on the skin of the cat’ s neck at the base of the skull.
Nanesite vsebino merilne kapalke na eno mesto kože vratu na zatilju glave mačke.
Do not apply the veterinary medicinal product to the surface of the cat’ s hair coat.
Zdravila ne nanašajte na površino dlake.
The veterinary medicinal product will prevent flea infestation for up to 6 weeks following a single administration depending on the level of environmental rechallenge.
Zdravilo po enkratni aplikaciji ščiti pred bolhami do 6 tednov, odvisno od ponovne infestacije iz okolja.
No adverse effects were observed in cats aged 8 weeks and older treated 7 times at two-week intervals with 3-5 times the recommended dose.
Pri mačkah starih 8 tednov ali več zdravljenih 7- krat v dvotedenskih intervalih s 3 – 5- kratnim priporočenim odmerkom ni bilo opaziti neželenih stranskih učinkov.
ATC Vet Code QP 53AX25
Oznaka ATC vet QP 53AX25
After topical administration at a single site on the cat’ s neck at the base of the skull, metaflumizone is rapidly distributed throughout the surface of the skin.
Po topikalnem nanosu na eno mesto vratu na zatilje glave mačke se metaflumizon hitro razporedi po površini kože.
After topical administration at a single site on the cat’ s neck at the base of the skull, metaflumizone levels in plasma were too low to allow the calculation of standard pharmacokinetic parameters.
Po topikalnem dajanju na eno mesto vratu na zatilje glave mačke, so bile koncentracije metaflumizona v plazmi prenizke za izračun standardnih farmakokinetičnih parametrov.
Synperonic NCA 830 Dimethyl sulfoxide Gamma-hexalactone
Synperonic NCA 830 Dimetilsulfoksid Gama- heksalakton
Do not store above 25 C
Ne shranjujte pri temperaturi nad 25ºC.
Box of 1 or 2 blister card of 3 x 0.80 ml pipettes Box of 1 or 2 blister card of 3 x 1.60 ml pipettes
Škatla z 1 ali 2 blistroma s 3 x 0, 80 ml merilnimi kapalkami Škatla z 1 ali 2 blistroma s 3 x 1, 60 ml merilnimi kapalkami
5 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
5 6. 6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi
Fort Dodge Animal Health Holland CJ van Houtenlaan 36 1381 CP Weesp, The Netherlands
Fort Dodge Animal Health Holland CJ van Houtenlaan 36 1381 CP Weesp, Nizozemska
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IMETNIK( I) DOVOLJENJ( A) ZA IZDELAVO ZDRAVILA, ODGOVOREN( ODGOVORNI) ZA SPROŠČANJE SERIJE
ProMeris 160 mg Spot-on for small cats {< 4 kg}
ProMeris 160 mg Spot- on za majhne mačke {≤ 4 kg}
Each 0.80 ml pipette delivers:
Vsaka 0, 80 ml pipeta vsebuje:
160 mg metaflumizone
160 mg metaflumizona
Box of 1 blister card of 3 x 0.80 ml pipettes Box of 2 blister cards of 3 x 0.80 ml pipettes
Škatla z 1 blistrom s 3 x 0, 80 ml merilnimi kapalkami Škatla z 2 blistroma s 3 x 1, 60 ml merilnimi kapalkami
For cats over 8 weeks of age.
Za mačke starejše od 8 tednov.
Consult your veterinarian before using the veterinary medicinal product on pregnant or lactating cats, or on sick or debilitated cats.
Pred uporabo zdravila pri brejih ali doječih mačkah ali pri bolanih ali izčrpanih mačkah se posvetujte s svojim veterinarjem.
EU/ 2/ 06/ 064/ 001 – 1 blister card of 3 pipettes of 0.80 ml EU/ 2/ 06/ 064/ 002 – 2 blister cards of 3 pipettes of 0.80 ml
EU/ 2/ 06/ 064/ 001 – 1 blister s 3 merilnimi kapalkamipo 0,. 80 ml EU/ 2/ 06/ 064/ 002 – 2 blistra s 3 merilnimi kapalkami po 0, 80 ml
ProMeris 320 mg Spot-on for large cats {> 4 kg}
ProMeris 320 mg Spot- on za velike mačke {> 4 kg}
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
NAVEDBA ZDRAVILNE( IH) UČINKOVIN( E) IN DRUGIH
Each 1.60 ml pipette delivers:
Vsaka 1, 60 ml pipeta vsebuje:
320 mg metaflumizone
320 mg metaflumizona
Box of 1 blister card of 3 x 1.60 ml pipettes Box of 2 blister cards of 3 x 1.60 ml pipettes
Škatla z 1 blistrom s 3 x 1, 60 ml merilnimi kapalkami Škatla z 2 blistroma s 3 x 1, 60 ml merilnimi kapalkami
EU/ 2/ 06/ 064/ 003– 1 blister card of 3 pipettes of 1.60 ml EU/ 2/ 06/ 064/ 004 – 2 blister cards of 3 pipettes of 1.60 ml
EU/ 2/ 06/ 064/ 003 – 1 blister s 3 merilnimi kapalkami po 1, 60 ml EU/ 2/ 06/ 064/ 004 – 2 blistra s 3 merilnimi kapalkami po 1, 60 ml
FOIL 0.80 ml
FOLIJA 0, 80 ml
ProMeris 160 mg Spot-on for small cats {≤ 4 kg}
ProMeris 160 mg Spot- on za majhne mačke {≤ 4 kg}
FOIL 1.60 ml
FOLIJA 1, 60 ml
16 MINIMUM PARTICULARS TO APPEAR ON PIPETTES
16 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MERILNIH KAPALKAH
17 MINIMUM PARTICULARS TO APPEAR ON PIPETTES
17 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MERILNIH KAPALKAH
19 PACKAGE LEAFLET ProMeris Spot-on for cats
19 NAVODILO ZA UPORABO ProMeris Spot- on za mačke
ProMeris 160 mg Spot-on for small cats ProMeris 320 mg Spot-on for large cats
ProMeris 160 mg Spot- on za majhne mačke ProMeris 320 mg Spot- on za velike mačke
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
NAVEDBA ZDRAVILNE( IH) UČINKOVIN( E) IN DRUGIH SESTAVIN
Active Substance Each ml contains 200 mg metaflumizone
Zdravilna učinkovina 1 ml vsebuje 200 mg metaflumizona
ProMeris for Small Cats (≤ 4 kg) ProMeris for Large Cats (> 4 kg)
mačke (≤ 4 kg) ProMeris za velike mačke
Do not use in kittens under 8 weeks of age.
Ne uporabljati pri mačkah mlajših od 8 tednov.
In sick or debilitated animals use only according to the benefit/ risk assessment.
Pri bolnih ali izčrpanih živalih uporabite le v skladu z oceno razmerja koristi/ tveganja odgovornega veterinarja.
Use only according to the benefit/ risk assessment by the responsible veterinarian.
Uporabite le v skladu z oceno razmerja koristi/ tveganja odgovornega veterinarja.
Cats above 8 weeks of age.
Mačke starejše od 8 tednov.
Apply the content of the pipette to a single spot on the skin of the cat’ s neck at the base of the skull.
Nanesite vsebino merilne kapalke na eno mesto kože vratu na zatilje glave mačke.
Part the fur on the cat’ s neck at the base of the skull until the skin is visible.
Nastavite vrh merilne kapalke na kožo.
21 Treatment schedule:
21 Načrt zdravljenja:
The veterinary medicinal product will prevent flea infestation for up to 6 weeks following a single administration depending on the level of environmental rechallenge.
Zdravilo po enkratni aplikaciji ščiti pred bolhami do 6 tednov, odvisno od ponovne okužbe iz okolja.
Care should be taken to ensure that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Poskrbite, da vsebina merilne kapalke ali nanešen odmerek ne pride v stik z očmi ali usti zdravljene živali in/ ali drugih živali.
Κύπρος Premier Shukuroglou Ltd.
24 Κύπρος Premier Shukuroglou Ltd.
What is ProteqFlu-Te?
Kaj je zdravilo ProteqFlu- Te?
ProteqFlu-Te is a vaccine for use in horses.
Zdravilo ProteqFlu- Te je cepivo, ki se uporablja pri konjih.
It contains parts of two equine influenza (flu) strains, which have been inserted into two canarypox vector viruses respectively, and a tetanus toxoid (chemically weakened toxins from the tetanus bacterium).
Vsebuje dele dveh sevov virusa konjske influence (gripe), vstavljenih v dva virusa vektorja (prenašalca) canarypox, in toksoid tetanusa (kemično oslabljene toksine iz bakterije tetanusa).
ProteqFlu-Te is available as a suspension for injection.
Zdravilo ProteqFlu- Te je na voljo v obliki suspenzije za injiciranje.
What is ProteqFlu-Te used for?
Za kaj se zdravilo ProteqFlu- Te uporablja?
ProteqFlu-Te is used to vaccinate horses from 4 months of age against equine influenza and tetanus.
Zdravilo ProteqFlu- Te se uporablja za cepljenje konjev, starih 4 mesece ali več, proti konjski influenci in tetanusu.
The vaccine reduces the clinical signs of equine influenza and the excretion (shedding) of the virus after infection.
Cepivo blaži klinične znake konjske influence in izločanje virusa po okužbi.
The vaccine also stimulates protection against tetanus to prevent mortality.
Cepivo spodbuja tudi zaščito proti tetanusu za preprečitev mortalnosti.
Tetanus is an acute, often fatal disease caused by the neurotoxin of the bacterium Clostridium tetani.
Tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin (živčni strup) bakterije Clostridium tetani.
The muscle stiffness usually starts from the jaw and neck, then affects the whole body.
Otrdelost mišic se navadno pojavi ob čeljustih in vratu, nato pa prizadene celotno telo.
Horses are among the most susceptible species to tetanus.
Konji so med živalskimi vrstami najbolj občutljivi na tetanus.
Horses should receive a primary vaccination, consisting of two injections at 5 - 6 months of age, given 4 - 6 weeks apart.
Konji potrebujejo primarno cepljenje, ki vključuje dve injiciranji pri starosti 5– 6 mesecev in se ju izvede 4– 6 tednov narazen.
This should be followed by revaccination 5 months later, and afterwards by yearly booster vaccinations.
Temu mora slediti ponovno cepljenje po 5 mesecih in nato letna poživitvena cepljenja.
In case of increased risk of infection or insufficient intake of colostrum (first milk), an additional initial injection can be given at the age of 4 months, followed by the full vaccination programme (primary vaccination and following revaccinations).
V primeru povečanega tveganja okužbe ali nezadostnega zaužitja kolostruma (prvega mleka), se lahko injicira dodatni začetni odmerek v starosti 4 mesecev, ki mu sledi popoln program cepljenja (primarno cepljenje, ki mu sledijo ponovitve).
How does ProteqFlu-Te work?
Kako zdravilo ProteqFlu- Te deluje?
ProteqFlu-Te is a vaccine which was produced with the use of recombinant technology.
Zdravilo ProteqFlu je cepivo, ki je bilo izdelano z rekombinantno tehnologijo.
This means that a gene from two different equine influenza strains (A/ equi-2/ Ohio/ 03 and A/ equi- 2/ Newmarket/ 2/ 93) was inserted in two live canary pox vector viruses respectively which made them capable to produce parts of these influenza strains (specific proteins).
To pomeni, da je bil gen iz dveh različnih sevov virusa konjske influence (A/ equi- 2/ Ohio/ 03 in A/ equi - 2/ Newmarket/ 2/ 93) vstavljen v dva živa virusa vektorja canarypox, zaradi česar sta postala sposobna tvoriti dele teh sevov influence (določene proteine).
The vaccine also contains a tetanus toxoid which is a tetanus toxin processed in order to decrease its toxic effect, but retain its antigenic power.
Cepivo vsebuje tudi toksoid tetanusa, ki je toksin tetanusa, obdelan tako, da je njegova strupenost manjša, vendar je pri tem ohranjeno antigensko delovanje.
When ProteqFlu-Te is given to horses, the animals’ immune system recognises the specific proteins from the equine influenza strains and the tetanus toxoid as ‘ foreign ’ and makes antibodies against them.
Kadar se zdravilo ProteqFlu- Te daje konjem, imunski sistem živali prepozna določene proteine iz sevov virusa konjske influence in toksoid tetanusa kot tujke ter začne proti njim tvoriti protitelesa.
The immune system will then be able to make those protective antibodies more quickly when the animal is naturally exposed to the equine flu viruses and the tetanus bacterium.
Imunski sistem bo nato pri naravni izpostavitvi virusom konjske gripe in bakteriji tetanusa sposoben hitreje ustvarjati ta zaščitna protitelesa.
This will help to protect against equine influenza and tetanus.
S tem pomagamo zaščititi živali proti konjski influenci in tetanusu.
The vaccine also contains an ‘ adjuvant’ to stimulate a better response.
Cepivo vsebuje tudi adjuvans, ki spodbudi boljši odziv.
How has ProteqFlu-Te been studied?
Kako je bilo zdravilo ProteqFlu- Te raziskano?
The safety of ProteqFlu-Te was studied in several studies under laboratory and field conditions in a large number of horses, of all ages (from 1 month to 40 years) and physiological status (foals, non-pregnant and pregnant female adults and male adults).
Varnost zdravila ProteqFlu- Te so raziskovali z več študijami, izvedenimi pod laboratorijskimi pogoji in pogoji na terenu na številnih konjih vseh starosti (od 1 meseca do 40 let) v različnih fizioloških stanjih (žrebeta, nebreje in breje odrasle samice ter samci).
It was concluded that the product is safe at very high doses in the target species, also in pregnant mares, whatever the stage of pregnancy.
Sklenili so, da je zdravilo pri ciljni živalski vrsti, tudi pri brejih kobilah, ne glede na stopnjo brejosti, varno tudi v zelo velikih odmerkih.
It was also shown that, when used in the horse, the live viruses contained in the vaccine do not spread, nor disseminate, nor replicate on the place of inoculation and do not recombine with another virus.
Dokazano je bilo tudi, da se živi virusi v cepivu ob uporabi pri konjih ne prenašajo, ne širijo in ne razmnožujejo na mestu inokulacije ter se ne rekombinirajo z drugimi virusi.
No environmental risk was identified through the use of this vaccine.
Pri uporabi tega cepiva niso ugotovili nobenih tveganj za okolje.
The effectiveness of ProteqFlu-Te was studied in several studies under laboratory and field conditions.
Učinkovitost zdravila ProteqFlu- Te so raziskovali z več študijami, izvedenimi pod laboratorijskimi pogoji in pogoji na terenu.
In studies under laboratory conditions, horses were challenged (infected) with equine influenza virus.
V študijah pod laboratorijskimi pogoji so konje okužili z virusom konjske influence.
The clinical signs and the excretion of the influenza virus after the challenge were compared between vaccinated and control animals (non vaccinated animals or vaccinated with a competitive product).
Klinične znake in izločanje virusa influence po okužbi so primerjali med cepljenimi in kontrolnimi živalmi (živali, ki jih niso cepili ali pa so jih cepili s konkurenčnim cepivom).
The production of protective levels of antibodies against the two influenza vaccine strains was measured in all studies.
V vseh študijah so merili tvorjenje zaščitnih ravni protiteles proti dvema sevoma cepiva influence.
Regarding tetanus, no challenge (infection) experiment was performed for ethical reason.
Iz etičnih razlogov za tetanus niso izvedli nobenega poskusa z izzivanjem okužbe.
The measure of effectiveness was the production of protective levels of antibodies against tetanus toxoid after vaccination.
Merilo učinkovitosti je bilo tvorjenje zaščitnih ravni protiteles proti tetanusnemu toksoidu po cepljenju.
What benefit has ProteqFlu-Te shown during the studies?
Kakšne koristi je zdravilo ProteqFlu- Te izkazalo med študijami?
The studies showed that ProteqFlu-Te is an effective vaccine in horses from 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality from 14 days after primary vaccination.
Študije so pokazale, da je zdravilo ProteqFlu učinkovito cepivo proti konjski influenci pri konjih, starih 4 mesece in več, za ublažitev kliničnih znakov in izločanja virusa po okužbi 14 dni po primernem cepljenju.
What is the risk associated with ProteqFlu-Te?
Kakšna tveganja so povezana z zdravilom ProteqFlu- Te?
Swelling may occur, (max. diameter 5 cm) which decreases within 4 days.
Pojavi se lahko oteklina (s premerom največ 5 cm), ki izgine v 4 dneh.
Pain and local hyperthermia (increase in body temperature) can occur in rare cases.
V redkih primerih se lahko pojavita bolečina in lokalna hipertermija (povišana telesna temperatura).
A slight increase in temperature (max.1.5 °C) may occur for one day, exceptionally for two days.
Rahlo povišanje temperature (največ 1, 5 °C) lahko traja en dan, izjemoma dva dni.
In exceptional circumstances, apathy and reduced appetite may be observed the day after vaccination.
V izjemnih okoliščinah se lahko dan po cepljenju pojavita apatičnost in zmanjšan tek.
Also in exceptional circumstances, a hypersensitivity (allergic) reaction can occur, which may require appropriate symptomatic treatment.
V izjemnih okoliščinah lahko pride tudi do preobčutljivostne reakcije, ki jo je treba ustrezno simptomatično zdraviti.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali nalepko na zunanji ovojnini.
Page 2/ 3 ©EMEA 2008 What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
Stran 2/ 3 ©EMEA 2008 Koliko časa mora preteči, preden se lahko žival zakolje in meso uporabi za prehrano ljudi (obdobje karence)?
The withdrawal period of the product is zero days.
Obdobje karence je nič dni.
Why has ProteqFlu-Te been approved?
Zakaj je bilo zdravilo ProteqFlu- Te odobreno?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProteqFlu-Te exceed the risks for the active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila ProteqFlu- Te pri aktivni imunizaciji konj, starih 4 mesece ali več, proti virusu konjske influence za ublažitev kliničnih znakov in izločanja virusa po okužbi in proti tetanusu za preprečevanje pogina večje od z njim povezanih tveganj.
The Committee recommended that ProteqFlu-Te be given a marketing authorisation.
Odbor je priporočil, da se za zdravilo ProteqFlu- Te odobri dovoljenje za promet.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji je opisano v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
Other information about ProteqFlu-Te:
Druge informacije o zdravilu ProteqFlu- Te:
The European Commission granted a marketing authorisation valid throughout the European Union, for ProteqFlu-Te to Merial S. A. S. on 6 March 2003.
Evropska komisija je dovoljenje za promet z zdravilom ProteqFlu- Te, veljavno po vsej Evropski uniji, odobrila družbi Merial S. A. S. dne 6. marca 2003.
This summary was last updated in September 2008.
Povzetek je bil nazadnje posodobljen 09- 2008.
Tradename
Izmišljeno ime
≥ 5.3 log10 FAID50 to 7.6 log10 FAID50 for both vCP2242 and vCP1533 per dose
≥ 5. 3 log10 FAID50
Intramuscular use
intramus
Suspension: vial (glass)
Viala (steklo)
1 ml
1 odmerek
0 days
Nič dn
≥ 30 UI/ ml for tetanus per dose
do 7. 6 log10 FAID50 za oba vCP2242 in vCP1533 v odmerku ≥30 IU/ ml za tetanus v odmerku
ProteqFlu-Te Suspension for injection for horses
ProteqFlu- Te Suspenzija za injiciranje za konje.
Influenza A/ equi-2/ Ohio/ 03 [H3N8] recombinant Canarypox virus (vCP2242) ≥ 5.3 log10 FAID*50 Influenza A/ equi-2/ Newmarket/ 2/ 93 [H3N8] recombinant Canarypox virus (vCP1533) ≥ 5.3 log10 FAID*50 *Fluorescent assay infectious dose 50% Clostridium tetani toxoid
Influenza A/ equi- 2/ Ohio/ 03 [H3N8] rekombinantni Canarypox virus (vCP2242) …..... ≥ 5, 3 log10 FAID* 50 Influenza A/ equi- 2/ Newmarket/ 2/ 93 [H3N8] rekombinantni Canarypox virus (vCP1533) ≥ 5, 3 log10 FAID* 50 * Fluorescenčni test infektivnega odmerka 50% Clostridium tetani toksoid....................................................................................................... ≥ 30 IU ** ** titer protiteles proti toksinu po večkratnem cepljenju v serumu morskih prašičkov po Ph.
Carbomer
FARMACEVTSKA OBLIKA
Suspension for injection.
4. 1 Ciljna živalska vrsta
Duration of immunity induced by the vaccination scheme:
Nastop imunosti 14. dan po končanem primarnem cepljenju Čas trajanja imunosti, ki ga spodbudi predvideni razpored cepljenja:
5 months after primary vaccination course and 1 year after the third vaccination.
5 mesecev po primarnem in eno leto po tretjem cepljenju.
2/ 17 Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
2/ 17 Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
• A transient swelling (max. diameter 5 cm) which regresses within 4 days may appear at the injection site. • Pain and local hyperthermia can occur in rare cases. • A slight increase in temperature (max.
Na mestu injiciranja se lahko pojavi prehodna oteklina (s premerom največ 5 cm), ki izgine v 4 • dneh.
1.5 °C) may occur for 1 day, exceptionally 2 days. • In exceptional circumstances, apathy and reduced appetite may be observed the day after vaccination. • In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
V redkih primerih se lahko pojavita bolečina in lokalno povišana temperatura. • Rahlo povišanje temperature (največ 1, 5 °C) lahko traja 1 dan, izjemoma 2 dni. • V izjemnih okoliščinah se lahko dan po cepljenju pojavita apatičnosti in zmanjšan tek. • V izjemnih okoliščinah lahko pride do preobčutljivostne reakcije, ki jo je treba ustrezno • simptomatično zdraviti.
No interaction has been observed when the vaccine was administered simultaneously, but at a separate site, with MERIAL’ s inactivated vaccine against rabies.
Pri sočasnem dajanju cepiva, vendar na različnih mestih niso ugotovili nobenih interakcij, z MERIALovim inaktiviranim cepivom proti steklini.
For the administration of the vaccine, use sterile and antiseptic-free and/ or disinfectant-free material.
Za pripravo in dajanje cepiva uporabljajte sterilen pribor, brez aseptikov in/ ali dezinficiensov.
Administer one dose (1ml), by intramuscular injection, preferably in the neck region, according to the following schedule: • Primary vaccination course: first injection from 5-6 months of age, second injection 4-6 weeks later • Revaccination:
Injicirajte 1 odmerek (1 ml) intramuskularno, priporočljivo v predel vratu, po naslednjem razporedu: • Primarno cepljenje: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje. • Revakcinacija: